Andere Sprachen Syros Pharmaceuticals, Inc.

Aktien

A3DT8V

US87184Q2066

SYRS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
5,1 ^USD	+2,00 %		+2,62 %	-34,53 %

14.05.	Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024
14.05.	Syros Pharmaceuticals, Inc. meldet Ergebnis fur das erste Quartal zum 31. Marz 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	14.05.
Syros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	09.04.
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	09.04.
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09.04.
Transcript : Syros Pharmaceuticals, Inc., 2023 Earnings Call, Mar 27, 2024	27.03.
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.03.
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene	25.03.
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial	25.03.
Sector Update: Health Care Stocks Mixed Late Afternoon	06.12.
Sector Update: Health Care	06.12.
Top Midday Gainers	06.12.
Transcript : Syros Pharmaceuticals, Inc. - Special Call	06.12.
Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine	06.12.
Top Premarket Decliners	27.11.
Transcript : Syros Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 14, 2023	14.11.
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Top Premarket Gainers	17.10.23
Sector Update: Health Care Stocks Lower Late Afternoon	02.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Syros Pharmaceuticals, Inc.

Aktien

A3DT8V

US87184Q2066

SYRS

Andere Sprachen

Filter